Non-Muscle Invasive Bladder Cancer (NMIBC) is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.
Non-Muscle Invasive Bladder Cancer Market Insight
The market size of Non-Muscle Invasive Bladder Cancer in 7MM in 2017 was USD 1,454 Million
NMIBC remains a very challenging disease to treat with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.
The current treatment regimen include surgery, intravesical immunotherapy (BCG) and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy which is the gold standard treatment for reducing tumor recurrence rates and preventing subsequent stage progression. Stage 0 bladder cancer is most often treated with TURBT with fulguration followed by intravesical therapy within 24 h. Sometimes no further treatment is needed. Cystoscopy is then done every 3–6 months to watch for signs that cancer has come back.
In addition to this, there is only one approved drug for the treatment of NMIBC namely Keytruda (pembrolizumab) which is approved for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
There are two types of intravesical therapy, namely immunotherapy and chemotherapy. BCG is the most common intravesical immunotherapy for treating early-stage bladder cancer. It is used to help keep cancer from growing, prevents it from relapse. BCG is a germ that is related to the one that causes tuberculosis (TB), but it does not usually cause serious disease.
Non-Muscle Invasive Bladder Cancer Market Drivers
- Imminent Launches
- Upsurge in Research and Development
- Enriched Understanding
- Increased Incidence
Non-Muscle Invasive Bladder Cancer Market Barriers
- High Cost of Therapy
- Expression Heterogeneity
- Lack of Approved Therapies
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Non-Muscle Invasive Bladder Cancer (NMIBC)
3. Competitive Intelligence Analysis for Non-Muscle Invasive Bladder Cancer (NMIBC)
4. Non-Muscle Invasive Bladder Cancer (NMIBC): Market Overview at a Glance
4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Share (%) Distribution in 2017
4.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Share (%) Distribution in 2030
5. Non-Muscle Invasive Bladder Cancer (NMIBC): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment and Management
8.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Non-Muscle Invasive Bladder Cancer (NMIBC): Seven Major Market Analysis
13.1. Key Findings
13.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size in 7MM
13.3. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in the United States
15.1.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Germany
15.3.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in France
15.4.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Italy
15.5.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Spain
15.6.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in the United Kingdom
15.7.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Japan
15.8.3. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/